Rhodiola Supplements UK — What the Evidence Says

What is Rhodiola?

Rhodiola (Rhodiola rosea) is a flowering plant that grows in cold, mountainous regions of Europe, Asia, and the Arctic. It belongs to the Crassulaceae family and is sometimes called golden root, arctic root, or roseroot, names that reflect both its appearance and the regions where it has traditionally been used.

Traditional use of Rhodiola spans centuries across Siberia, Scandinavia, and parts of Central Asia. In these cultures, it was used to support physical endurance and manage the demands of harsh environments. It features in traditional Scandinavian and Russian folk medicine, and the Soviet Union studied it extensively in the mid-twentieth century as part of research into what were then called adaptogens, a term used to describe plants studied for their potential role in stress response.

Today, Rhodiola extract appears in a wide range of supplements, particularly those marketed around mental performance, energy, and stress. Supplement products typically use a standardised root extract, specifying concentrations of its key active compounds. The quality and transparency of that standardisation is central to how Cogniscore evaluates any product containing this ingredient.

Key Active Compounds

Rhodiola rosea contains several bioactive compounds that researchers and supplement manufacturers have focused on. The most studied are the rosavins, a group that includes rosavin, rosarin, and rosin. These glycosides are found almost exclusively in Rhodiola rosea, which makes them useful as markers for species authentication. A standardised extract specifying 3% rosavins is the most common benchmark used in clinical research.

Salidroside (also called tyrosol glycoside) is the second key compound. It is present in several Rhodiola species and has been the subject of a significant amount of laboratory research. The typical clinical benchmark for salidroside is 1%, used alongside the rosavin specification.

P-tyrosol and various flavonoids are also present in the plant and have been examined in research, though they are less consistently used as quality markers in supplement labelling.

Cogniscore looks for explicit standardisation figures on product labels and Certificates of Analysis (COAs). A product that states only "Rhodiola rosea extract" without specifying rosavin and salidroside percentages cannot be compared against clinical trial doses. That missing information directly affects its disclosure score.

Benefit Areas Studied in Research

Mental fatigue. Rhodiola rosea has been studied in clinical trials examining mental fatigue, particularly fatigue arising from prolonged cognitive work or sleep restriction. Several human trials have used standardised extracts in the 200mg to 600mg range to examine outcomes such as speed and accuracy on cognitive tasks. Research has looked at both single-dose and repeated-dose protocols across this area.

Stress adaptation. A number of studies have looked at Rhodiola in the context of stress-induced fatigue. Research has examined outcomes in populations exposed to occupational stress, night shifts, and examination periods. These trials have used standardised SHR-5 extracts, a specific preparation that specifies rosavin and salidroside content, to examine whether measurable changes in fatigue-related outcomes occur under controlled conditions.

Mood. Some clinical research has examined Rhodiola in relation to mood-related outcomes. A small number of human trials have used standardised extracts over periods of several weeks to examine self-reported mood and psychological wellbeing measures. The sample sizes in this area tend to be small, and results should be read with that in mind.

Sustained attention. Research has examined Rhodiola in relation to sustained attention and mental performance under fatigue. Human trials in this area have tended to use single doses taken before periods of demanding cognitive work, with researchers measuring speed and accuracy outcomes over time. Study durations and populations vary across the available literature.

The Science and Research

The clinical research base for Rhodiola rosea is small but contains several human RCTs, which carry more weight than animal or in vitro studies. The three references below represent the most cited human research and give a clear picture of the doses and study types involved.

Shevtsov et al. (2003), Phytomedicine. This randomised controlled trial examined the effects of two doses of a standardised SHR-5 Rhodiola extract (170mg and 185mg) on mental performance and fatigue in military cadets under sleep deprivation and academic stress. Researchers measured a composite anti-fatigue index derived from tests of attention, speed, and accuracy over a single night period. The study type was a human RCT. A key limitation is the short duration of the intervention, which lasted only one night, and the specific population used (young military cadets) limits how broadly the findings can be read.

Darbinyan et al. (2000), Phytomedicine. This double-blind, crossover RCT examined the same SHR-5 extract at 370mg per day in physicians working night shifts. Researchers measured performance on tests of associative thinking, short-term memory, and mental calculation over a two-week period. The study found a statistically significant period during active supplementation compared to placebo, though the crossover design and relatively small sample (56 participants) are worth noting. Industry involvement in the funding of some SHR-5 research is a recurring limitation across this literature.

Cropley et al. (2015), Phytotherapy Research. This study examined the effects of Rhodiola rosea extract at 400mg per day over a four-week period in healthy adults reporting life stress. The researchers looked at stress, anxiety, and cognitive function using validated self-report scales and cognitive task batteries. The study type was a human RCT with a placebo arm. Limitations include a relatively small sample size and reliance on self-report measures for some outcomes.

Across this literature, the most commonly studied dose range is 200mg to 600mg of standardised extract per day, using preparations specifying 3% rosavins and 1% salidroside. Studies below this standardisation threshold are harder to compare. Animal and in vitro studies exist across all the benefit areas noted above, but human RCT evidence remains limited in both scale and duration.

How Cogniscore Evaluates Rhodiola

When Cogniscore scores a product containing Rhodiola, the first check is the dose per serving relative to the clinical trial range of 200mg to 600mg of standardised extract. A product disclosing a dose within this range scores higher than one that discloses only a total blend weight where Rhodiola cannot be individually assessed. Products that do not disclose a per-ingredient dose at all are scored as limited disclosure in this area.

Standardisation is equally important. The clinical research on Rhodiola has consistently used extracts specifying 3% rosavins and 1% salidroside. A product that names only "Rhodiola rosea extract" without specifying these figures cannot be compared against the research. Cogniscore also looks for third-party Certificates of Analysis confirming the stated standardisation, since label claims alone carry less weight than independently verified testing. Products that provide a COA aligned to clinical benchmarks score higher under the third-party verification component of the full Cogniscore methodology.

Top Rated Products Containing Rhodiola

Ranked by Cogniscore — highest disclosure scores first. Scores reflect what brands publicly disclose, not product quality or efficacy.

No scored products containing Rhodiola are currently listed. Check back as the database grows.

Frequently Asked Questions

This page was generated with AI assistance based on publicly available data. Report an error: corrections@cogniscore.co.uk